Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Chin Med J (Engl). 2021 Dec 22;135(3):261-267. doi: 10.1097/CM9.0000000000001932.
Antibody-drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high anti-tumor activity of small molecular cytotoxic payloads. The anti-tumor activity of ADCs is mainly achieved by the direct blocking of the receptor by monoclonal antibodies, direct action and bystander effect of cytotoxic drugs, and antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. ADCs have been used in adjuvant therapy and rescue treatment of human epidermal receptor 2 (HER2)-positive breast cancer, greatly improving the prognosis of breast cancer patients. Several ongoing clinical trials of ADC for breast cancer and other solid tumors proved the potential of ADCs will provide more promising treatment options for patients with malignant tumors. This review introduces the mechanism and latest clinical progress of ADC drugs approved for HER2-positive breast cancer to guide clinical practice and conduct research.
抗体药物偶联物 (ADC) 将单克隆抗体的高特异性与小分子细胞毒性有效载荷的高抗肿瘤活性相结合。ADC 的抗肿瘤活性主要通过单克隆抗体直接阻断受体、细胞毒性药物的直接作用和旁观者效应、抗体依赖性细胞介导的细胞毒性和补体依赖性细胞毒性来实现。ADC 已用于人表皮生长因子受体 2（HER2）阳性乳腺癌的辅助治疗和挽救治疗，极大地改善了乳腺癌患者的预后。几项正在进行的 ADC 治疗乳腺癌和其他实体瘤的临床试验证明了 ADC 的潜力，为恶性肿瘤患者提供了更有前景的治疗选择。本综述介绍了已批准用于治疗 HER2 阳性乳腺癌的 ADC 药物的作用机制和最新临床进展，以指导临床实践和开展研究。
